Christina Mulkey, NP
Gerontology · Wheat Ridge, CONPI 1922547967
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.4% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,032 and has fallen 75.1% since, to $257 in 2025.
Across 86 payments — averaging $23.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$395
- Pfizer$278
- Johnson & Johnson$236
- Dexcom, Inc.$162
- Otsuka America Pharmaceutical, Inc.$138
- Amgen$124
- plus $695 from 20 others
What the payments were for
- Food & beverage$1,93395%
- Education$935%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 22 | $395 |
| Pfizer | 14 | $278 |
| Johnson & Johnson | 5 | $236 |
| Dexcom, Inc. | 3 | $162 |
| Otsuka America Pharmaceutical, Inc. | 7 | $138 |
| Amgen | 5 | $124 |
| Novartis | 4 | $89 |
| Astellas Pharma US Inc | 1 | $85 |
| Novo Nordisk | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| AstraZeneca | 2 | $36 |
| Sanofi-aventis U.S. LLC | 1 | $30 |
| Sanofi Pasteur Inc. | 1 | $30 |
| Biohaven Pharmaceuticals, Inc. | 1 | $30 |
| Boston Scientific | 1 | $25 |
| Vibrant Gastro, Inc. | 1 | $24 |
| Abiomed | 1 | $24 |
| Alkermes, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Inogen, Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Merck | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$150
- DEXCOM G7 GSS (161)$122
How this compares
$2,026 in reported general payments places this provider in the 80th percentile of 85 gerontology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $64,203 |
| RexultiBrexpiprazole | 17 | $42,979 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $32,184 |
| XareltoRivaroxaban | 31 | $25,437 |
| EliquisApixaban | 32 | $25,243 |
| MyrbetriqMirabegron | 32 | $22,916 |
| VraylarCariprazine Hcl | 12 | $20,116 |
| FarxigaDapagliflozin Propanediol | 13 | $9,781 |
| Atrovent HfaIpratropium Bromide | 17 | $9,293 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 17 | $5,467 |
| RestasisCyclosporine | 11 | $5,443 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,305 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 23 | $5,128 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,019 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $4,415 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $74 | $64,20358 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $138 | $42,97917 claims |
| PfizerEliquis, Abrysvo | $278 | $30,71049 claims |
| AbbVieVraylar, Restasis | $395 | $25,55923 claims |
| Johnson & JohnsonXarelto | $236 | $25,43731 claims |
| Astellas Pharma US IncMyrbetriq | $85 | $22,91632 claims |
| AstraZenecaFarxiga | $36 | $9,78113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 85 gerontology providers in Colorado.
Other gerontology in Wheat Ridge
- Nylah BassWheat Ridge$1K
- Thomas SecWheat Ridge$892
- Shannon WilliamsonWheat Ridge$340
- Peter HuntWheat Ridge$308
- Kimberly RobertsonColorado Springs$9K
- Melinda McClendonColorado Springs$8K
- Nicole ChiekaColorado Springs$6K
- Ashley ReadLoveland$5K
- Rhiannon SundayColorado Springs$5K
- Kimberly CunninghamAurora$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.